Oncimmune Holdings（OCY）株式概要プレシジョン・メディシン企業であるOncimmune Holdings plcは、免疫腫瘍学、自己免疫疾患、感染症における自己抗体バイオマーカー・プロファイリングをヨーロッパおよび国際的に提供している。 詳細OCY ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性2/6配当金0/6報酬過去5年間の収益は年間13.9%増加しました。 リスク分析マイナスの株主資本 過去1年間で株主の希薄化は大幅に進んだ 意味のある時価総額がありません ( €1M )German市場と比較して、過去 3 か月間の株価の変動が非常に大きい+1 さらなるリスクすべてのリスクチェックを見るOCY Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW488,504 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA488,504 investors already sharing narrativesYour Fair Value€Current Price€0.01194.2% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-9m5m2016201920222025202620282031Revenue UK£4.9mEarnings UK£849.1kAdvancedSet Fair ValueView all narrativesOncimmune Holdings plc 競合他社EpigenomicsSymbol: DB:ECXMarket cap: €824.4kbioXXmedSymbol: DB:T5OMarket cap: €225.6kGenetic AnalysisSymbol: DB:8V8Market cap: €47.0mHeidelberg PharmaSymbol: XTRA:HPHAMarket cap: €119.3m価格と性能株価の高値、安値、推移の概要Oncimmune Holdings過去の株価現在の株価UK£0.01152週高値UK£0.2852週安値UK£0.011ベータ1.811ヶ月の変化0%3ヶ月変化-91.73%1年変化-95.53%3年間の変化-99.13%5年間の変化-98.64%IPOからの変化-99.27%最新ニュースNew Risk • Feb 13New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €9.29m (US$9.66m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Negative equity (-UK£2.4m). Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Market cap is less than US$10m (€9.29m market cap, or US$9.66m). Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£207k net loss next year). Share price has been volatile over the past 3 months (7.3% average weekly change). Revenue is less than US$5m (UK£2.7m revenue, or US$3.4m).Reported Earnings • Feb 11Full year 2024 earnings released: UK£0.047 loss per share (vs UK£0.085 loss in FY 2023)Full year 2024 results: UK£0.047 loss per share (improved from UK£0.085 loss in FY 2023). Revenue: UK£2.74m (up 138% from FY 2023). Net loss: UK£3.50m (loss narrowed 43% from FY 2023). Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has fallen by 61% per year, which means it is significantly lagging earnings.お知らせ • Feb 03Oncimmune Holdings plc, Annual General Meeting, Feb 27, 2025Oncimmune Holdings plc, Annual General Meeting, Feb 27, 2025. Location: 201 temple chambers, 3 7 temple avenue, ec4y 0dt, london United Kingdomお知らせ • Jan 31Oncimmune Holdings plc Provides Revenue Guidance for the First Half and for the Fiscal Year 2025Oncimmune Holdings plc provided revenue guidance for the first half of fiscal year 2025. For the period, the company's revenue is likely to be approximately £1.4 million, an increase of circa 20% on the prior year (£1.19 million) and the Company continues to add to its broad pipeline of potential contracts. For the year 2025, the company expects revenue to be in the region of £4 million, which would be an uplift of 33% vs FY2024 and growth of around 250% vs FY2023. The company expects to have much greater visibility on its revenue in the second half of the financial year.New Risk • Dec 08New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended February 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Negative equity (-UK£1.3m). Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported February 2024 fiscal period end). Currently unprofitable and not forecast to become profitable next year (UK£1.4m net loss next year). Share price has been volatile over the past 3 months (11% average weekly change). Revenue is less than US$5m (UK£1.2m revenue, or US$1.5m). Market cap is less than US$100m (€20.9m market cap, or US$22.1m).New Risk • Nov 14New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 51% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Negative equity (-UK£1.3m). Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£1.4m net loss next year). Revenue is less than US$5m (UK£1.2m revenue, or US$1.5m). Market cap is less than US$100m (€20.8m market cap, or US$21.9m).最新情報をもっと見るRecent updatesNew Risk • Feb 13New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €9.29m (US$9.66m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Negative equity (-UK£2.4m). Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Market cap is less than US$10m (€9.29m market cap, or US$9.66m). Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£207k net loss next year). Share price has been volatile over the past 3 months (7.3% average weekly change). Revenue is less than US$5m (UK£2.7m revenue, or US$3.4m).Reported Earnings • Feb 11Full year 2024 earnings released: UK£0.047 loss per share (vs UK£0.085 loss in FY 2023)Full year 2024 results: UK£0.047 loss per share (improved from UK£0.085 loss in FY 2023). Revenue: UK£2.74m (up 138% from FY 2023). Net loss: UK£3.50m (loss narrowed 43% from FY 2023). Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has fallen by 61% per year, which means it is significantly lagging earnings.お知らせ • Feb 03Oncimmune Holdings plc, Annual General Meeting, Feb 27, 2025Oncimmune Holdings plc, Annual General Meeting, Feb 27, 2025. Location: 201 temple chambers, 3 7 temple avenue, ec4y 0dt, london United Kingdomお知らせ • Jan 31Oncimmune Holdings plc Provides Revenue Guidance for the First Half and for the Fiscal Year 2025Oncimmune Holdings plc provided revenue guidance for the first half of fiscal year 2025. For the period, the company's revenue is likely to be approximately £1.4 million, an increase of circa 20% on the prior year (£1.19 million) and the Company continues to add to its broad pipeline of potential contracts. For the year 2025, the company expects revenue to be in the region of £4 million, which would be an uplift of 33% vs FY2024 and growth of around 250% vs FY2023. The company expects to have much greater visibility on its revenue in the second half of the financial year.New Risk • Dec 08New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended February 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Negative equity (-UK£1.3m). Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported February 2024 fiscal period end). Currently unprofitable and not forecast to become profitable next year (UK£1.4m net loss next year). Share price has been volatile over the past 3 months (11% average weekly change). Revenue is less than US$5m (UK£1.2m revenue, or US$1.5m). Market cap is less than US$100m (€20.9m market cap, or US$22.1m).New Risk • Nov 14New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 51% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Negative equity (-UK£1.3m). Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£1.4m net loss next year). Revenue is less than US$5m (UK£1.2m revenue, or US$1.5m). Market cap is less than US$100m (€20.8m market cap, or US$21.9m).Breakeven Date Change • Oct 24No longer forecast to breakevenThe analyst covering Oncimmune Holdings no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of UK£552.0k in 2025. New forecast suggests the company will make a loss of UK£207.0k in 2025.New Risk • Sep 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (15% average weekly change). Minor Risk Market cap is less than US$100m (€17.0m market cap, or US$18.9m).お知らせ • Aug 10Oncimmune Holdings plc Reaffirms Revenue Guidance for the Fiscal Year 2024 and Provides Earnings Guidance for the Fiscal Year 2025Oncimmune Holdings plc reaffirmed revenue guidance for the fiscal year 2024 and provided earnings guidance for the fiscal year 2025. The continued commercial traction, and expected acceleration due to the new commercial team fully bedding in, give Oncimmune's Board confidence in its revenue guidance for fiscal year 2024 of approximately £3 million (2023: £1.15 million from continuing operations). On the back of continued revenue growth, the Board expects the Company to achieve profitability in fiscal year 2025.New Risk • Jun 10New major risk - Negative shareholders equityThe company has negative equity. Total equity: -UK£1.3m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£6.1m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Negative equity (-UK£1.3m). Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£1.1m net loss next year). Revenue is less than US$5m (UK£1.2m revenue, or US$1.5m). Market cap is less than US$100m (€14.0m market cap, or US$15.1m).お知らせ • May 19Oncimmune Holdings plc to Report First Half, 2024 Results on May 21, 2024Oncimmune Holdings plc announced that they will report first half, 2024 results on May 21, 2024Board Change • May 16Less than half of directors are independentThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 3 new directors. 4 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). Member of Scientific Board Ola Winqvist is the most experienced director on the board, commencing their role in 2018. Independent Non-Executive Director John Goold was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.Reported Earnings • Mar 01Full year 2023 earnings released: UK£0.085 loss per share (vs UK£0.13 loss in FY 2022)Full year 2023 results: UK£0.085 loss per share (improved from UK£0.13 loss in FY 2022). Revenue: UK£1.15m (down 62% from FY 2022). Net loss: UK£6.15m (loss narrowed 33% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 53% per year, which means it is performing significantly worse than earnings.お知らせ • Mar 01Oncimmune Holdings plc Provides Earnings Guidance for the Year 2024Oncimmune Holdings plc provided earnings guidance for the year 2024. For the period, the company expects revenue to be approximately £3 million, compared with Fiscal Year 2023 revenue from continuing operations of £1.2 million, a growth rate of 150%. Coming up to the end of H1 Fiscal Year 2024, work to achieve approximately 75% of the forecast Fiscal Year 2024 revenue has been secured, with the majority of samples received or expected imminently allowing lab work to begin and revenue to be recognised in due course.お知らせ • Feb 02Oncimmune Holdings plc, Annual General Meeting, Feb 26, 2024Oncimmune Holdings plc, Annual General Meeting, Feb 26, 2024, at 10:00 Coordinated Universal Time. Location: At the offices of Singer Capital Markets, 1 Bartholomew Lane London United KingdomNew Risk • Jan 30New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended August 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Negative equity (-UK£4.2m). Revenue has declined by 14% over the past year. Minor Risks Latest financial reports are more than 6 months old (reported August 2022 fiscal period end). Share price has been volatile over the past 3 months (9.6% average weekly change). Revenue is less than US$5m (UK£3.0m revenue, or US$3.8m). Market cap is less than US$100m (€21.5m market cap, or US$23.3m).お知らせ • Nov 30Oncimmune Holdings plc Announces Board ChangesOncimmune Holdings plc announced on 12 October 2023, Dr. Annalisa Jenkins has decided to step down from the Board and a new Senior Independent Non-Executive Director, Sally Waterman, has been appointed. The transition of Annalisa's responsibilities has now been completed and she has therefore ceased to be a director with immediate effect.Board Change • Nov 02Less than half of directors are independentThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 4 new directors. 5 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Non-Executive Director Annalisa Jenkins is the most experienced director on the board, commencing their role in 2018. Senior Independent Non-Executive Director Sally Waterman was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.お知らせ • Oct 12Oncimmune Holdings plc Announces Changes to the BoardOncimmune's new focus on its ImmunoINSIGHTS business, having disposed of its early cancer diagnostic business in May 2023, the composition of Oncimmune's board of directors (the "Board") is undergoing further change. Tim Bunting, who has been a director of Oncimmune since 2016, has stepped down from the Board with immediate effect. Tim was one of Oncimmune's earliest investors and continued to support it for over 15 years, many of them as a non-executive director. Tim remains a major shareholder of Oncimmune, having supported its latest fundraise in December 2022, and has given his full backing to the Company's new management team. Dr Annalisa Jenkins has also decided to step down from the Board by the end of 2023. Annalisa has been a director of Oncimmune since January 2018 and has served as the Company's Senior Independent Director and Chair of its Remuneration Committee. To replace Dr Annalisa Jenkins, Oncimmune announced the appointment of Sally Waterman. Sally has over 30 years of strategic and operational experience in the life science industry, including leading R&D and extensive involvement in M&A, and has worked for large pharma, small biotech/biopharma and contract service companies. Once all of the changes set out above are completed, and following the departure of Andrew Unitt as previously announced on 12 July 2023, the Board will consist of Alistair Macdonald (Non-executive Chair), Dr Sally Waterman (Senior Independent Non-executive Director and Chair of the Remuneration Committee), John Goold (Independent Non-executive Director and Chair of the Audit Committee) and Martin Gouldstone (Chief Executive Officer).お知らせ • Aug 02+ 1 more updateOncimmune Holdings plc Announces Executive ChangesOncimmune Holdings plc announced that Martin Gouldstone has started as the Company's new Chief Executive Officer and joined the Board of Directors. With Martin as Chief Executive Officer, Ron Kirschner, who was appointed as acting Chief Executive Officer in June, will be taking up the role of Chief Operating Officer and has stepped down from the Board. Ron remains Oncimmune's Company Secretary.お知らせ • May 23Freenome Holdings, Inc. acquired Oncimmune Limited and Oncimmune Europe GmbH from Oncimmune Holdings plc (AIM:ONC) for £13 million.Freenome Holdings, Inc. acquired Oncimmune Limited and Oncimmune Europe GmbH from Oncimmune Holdings plc (AIM:ONC) for £13 million on May 22, 2023. The consideration of £13 million is in cash, structured as consideration for equity and debt repayment, of which £1.3 million in cash is being held in escrow for 12 months in the event of any claim by Freenome against the customary warranties and indemnity given to Freenome in the sale and purchase agreement. Separately, Oncimmune Germany GmbH, Oncimmune Holdings' wholly-owned pharma services business trading as ImmunoINSIGHTS, and Freenome have also signed a long-term Master Services Agreement. Oncimmune Holdings has an existing debt facility with IPF Management SA with an outstanding principal balance of €11.6 million prior to this transaction. In connection with the transaction, Oncimmune has agreed to repay €7.2 million (being €5.6 million of principal and €1.6 million of interest) of the outstanding IPF Facility. The Board of Oncimmune Holdings considers that the repayment of debt under the IPF Facility, the repayment profile of the new IPF Facility, together with the net proceeds from the transaction, removes any material uncertainty as regards going concern. Phil Davies, Harry Gooden, George Tzimas and James Fischer of Nplus1 Singer Advisory LLP acted as the financial advisor to Oncimmune Holdings plc (AIM:ONC).Freenome Holdings, Inc. completed the acquisition of Oncimmune Limited and Oncimmune Europe GmbH from Oncimmune Holdings plc (AIM:ONC) for £13 million on May 22, 2023.お知らせ • Feb 04Oncimmune Holdings plc, Annual General Meeting, Feb 27, 2023Oncimmune Holdings plc, Annual General Meeting, Feb 27, 2023, at 10:00 Coordinated Universal Time. Location: offices of Pinsent,Masons LLP, 30 Crown Place, Earl Street, London, EC2A 4ES London United Kingdomお知らせ • Jan 13Oncimmune Holdings plc Announces Appointment of John Goold as Non-Executive DirectorOncimmune Holdings plc announced that further to the announcement made on 7 December 2022, John Goold has been appointed to the Board of the Company as Non-Executive Director with immediate effect, following the successful completion of customary due diligence checks by the Company's Nominated Adviser. Additional Information in respect of the AIM Rules: The following information regarding the appointment of John Howard Goold, aged 51, is disclosed under Schedule 2(g) of the AIM Rules for Companies.お知らせ • Dec 15Oncimmune Holdings plc has completed a Follow-on Equity Offering in the amount of £2.1 million.Oncimmune Holdings plc has completed a Follow-on Equity Offering in the amount of £2.1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 2,622,221 Price\Range: £0.45 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 2,044,446 Price\Range: £0.45Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Senior Independent Non-Executive Director Annalisa Jenkins was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Sep 22Full year 2022 earnings released: UK£0.14 loss per share (vs UK£0.072 loss in FY 2021)Full year 2022 results: UK£0.14 loss per share (further deteriorated from UK£0.072 loss in FY 2021). Revenue: UK£3.86m (up 3.7% from FY 2021). Net loss: UK£9.51m (loss widened 106% from FY 2021). Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.Buying Opportunity • Aug 01Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 29%. The fair value is estimated to be €1.19, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 92% over the last 3 years. Earnings per share has grown by 17%.お知らせ • Jul 08Oncimmune Holdings plc Announces Board ChangesOncimmune Holdings plc announced the appointment of Alistair Macdonald as Non-executive Chair, effective immediately. Alistair succeeds Meinhard Schmidt as Chair of the Board, who has retired from the Board. Alistair brings a wealth of knowledge in the pharma services sector, developed through his 25-year career in life sciences, culminating in his role as CEO of leading, integrated CRO Syneos Health Inc. (Nasdaq: SYNH; market cap c.$6.6 billion) ("Syneos"), which he held for 6 years, before which he was CEO of INC Research which merged with inVentiv Health to become Syneos in 2017. During his time with INC and then Syneos, revenue grew from $20m to over $5.0 billion. Prior to becoming a CEO, Alistairled multiple functions including Global Business Development and Marketing, Alliances Development and Delivery, Global Oncology, and Clinical Development Services. Over the last 25 years, he has held management positions in the pharmaceutical industry across manufacturing, consultancy, business and corporate development, data management and clinical operations. Alistair retired as CEO of Syneos Health in April 2022, a company that he led post-merger through further substantial organic as well as inorganic growth. Alistair led the merger that formed Syneos, which brought together approximately 24,000 employees serving customers in 110 countries with innovative, end-to-end solutions to accelerate their clinical development and commercialisation timelines. Until recently, Alistair has also served as Chair of ACRO, the Association of Clinical Research Organisations, having been on its board for approximately seven years.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 1 highly experienced director. 2 independent directors (3 non-independent directors). Senior Independent Non-Executive Director Annalisa Jenkins was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Mar 02First half 2022 earnings: EPS in line with expectations, revenues disappointFirst half 2022 results: UK£0.07 loss per share (down from UK£0.041 loss in 1H 2021). Revenue: UK£1.43m (down 22% from 1H 2021). Net loss: UK£4.86m (loss widened 87% from 1H 2021). Revenue missed analyst estimates by 34%. Over the next year, revenue is forecast to grow 316%, compared to a 64% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth.お知らせ • Feb 25+ 1 more updateOncimmune Holdings Ordinary Shares to Be Deleted from Other OTCOncimmune Holdings plc's Ordinary Shares will be deleted from other OTC effective from February 24, 2022 due to Inactive Security.お知らせ • Feb 18Oncimmune Holdings plc Announces EarlyCDT Lung Test Approved by Ministry of Health for Aragon, SpainOncimmune Holdings plc announced that the Regional Ministry of Health for Aragon, Spain has announced that the Company's Early CDT Lung blood test is to be adopted by the Thoracic Surgery Unit of the University Hospital Miguel Servet, Zaragoza, for use on solitary pulmonary nodules. This approval follows the issuing of a favourable assessment and report by the Evaluation Committee of the Aragonese Health System having met the necessary criteria with regards to efficacy and safety. The issuing of this positive assessment by the Aragon Public Health Service and the subsequent approval is considered an important development by Oncimmune and its Spanish distributor, Sabartech, towards the adoption of the blood test by other regional public health systems in Spain. This latest approval in Spain follows an earlier announcement on 2 November 2021 that EarlyCDT Lung had been authorised for use within the Spanish Public Health Service by the Galician Health Service (SERGAS), the first public health service in Spain to use the EarlyCDT Lung test.Reported Earnings • Nov 04Full year 2021 earnings released: UK£0.072 loss per share (vs UK£0.13 loss in FY 2020)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: UK£3.72m (up UK£3.21m from FY 2020). Net loss: UK£4.63m (loss narrowed 45% from FY 2020). Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has increased by 22% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Jul 24Oncimmune Holdings plc Announces the Pre-Publication of the First Results from Its Collaboration with Cedars-Sinai Medical Center in Los AngelesOncimmune Holdings plc announced the pre-publication of the first results from its collaboration with Cedars-Sinai Medical Center in Los Angeles, entitled: "Paradoxical Sex-Specific Patterns of Autoantibodies Response to SARS-CoV-2 Infection"1. The paper focuses on the characterisation of sex-specific prevalence and selectivity of autoantibody responses to the SARS-CoV-2 virus. Since the beginning of the COVID-19 pandemic, there has been an unprecedented number of initiatives from the life sciences industry and research institutions to understand and respond to the effects of COVID-19, but despite first generation vaccines now being deployed to fight the disease, the need to expand understanding of the immune response to SARS-CoV-2 still exists. The results of this study demonstrate the potential of the SeroTagTM Infectious Diseases discovery array to enable a better understanding of how SARS-CoV-2 stimulates the immune reaction and predicts responses to vaccines and therapeutics against the virus. The aim of this initial research project was to use the SeroTag Infectious Diseases discovery array to detect autoantibodies to over 90 antigens previously linked to a range of classic autoimmune diseases. The researchers sought to comprehensively examine the diversity of autoantibody responses in male and female health care workers who were exposed to SARS-CoV-2 and were asymptomatic, or experienced minor symptoms.お知らせ • May 21Oncimmune Holdings plc Presents Clinical Abstracts on Melflufen At the 2021 American Society of Clinical OncologyOncopeptides AB (publ) announces that three abstracts with data on melflufen (INN melphalan flufenamide) in relapsed refractory multiple myeloma, RRMM, have been accepted by the 2021 American Society of Clinical Oncology, ASCO, and have now been published online. The clinical data presentations include updates on Oncopeptides' ANCHOR and LIGHTHOUSE studies as well as a pooled analysis of the O-12-M1 and HORIZON studies in patients who have been exposed to or become refractory to prior alkylators. Below is a brief description of the abstracts that have been accepted by the ASCO. They will be available online at https://www.asco.org, on May 19th at 23:00 (CET). 1. ANCHOR (OP-104): MELFLUFEN PLUS DEXAMETHASONE AND BORTEZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS The ANCHOR study determined that the optimal dose of melflufen is 30 mg plus dexamethasone and bortezomib and the results showed clinical activity in heavily pretreated RRMM patients. Recruitment for this study is ongoing and updated data including efficacy and safety will be presented at ASCO. 2. LIGHTHOUSE (OP-108): A PHASE 3 STUDY OF MELFLUFEN IN COMBINATION WITH DEXAMETHASONE AND DARATUMUMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS The phase 3 LIGHTHOUSE study is a randomized, controlled, open-label study of melflufen plus dexamethasone in combination with daratumumab vs daratumumab alone in patients with RRMM previously treated with an immunomodulatory agent and a proteasome inhibitor, similar to the indication for daratumumab monotherapy. The primary objective is superiority of PFS. Key secondary endpoints include ORR (= PR), DOR, and safety. Patient recruitment is ongoing with a planned enrolment of 240 patients. 3. A POOLED ANALYSIS OF THE O-12-M1 AND HORIZON STUDIES: MELFLUFEN PLUS DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS (RRMM) WHO ARE EXPOSED OR REFRACTORY TO PRIOR ALKYLATORS This pooled analysis of the O-12-M1 and HORIZON studies showed that melflufen in combination with dexamethasone showed meaningful efficacy and demonstrated a clinically manageable safety profile in patients with RRMM who had been exposed or become refractory to prior alkylators. PEPAXTO® (melphalan flufenamide, also known as melflufen), in combination with dexamethasone, was granted accelerated approval by the FDA on February 26, 2021, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD38-directed monoclonal antibody.お知らせ • May 13Oncopeptides AB (publ) Presents New Clinical and Preclinical Melflufen Data At the Upcoming European Hematology Association MeetingOncopeptides AB (publ) announces that new clinical and preclinical data have been accepted by the European Hematology Association, EHA, and been published online. The clinical data presentation contains interim results from the phase 2 BRIDGE study supporting the use of melflufen in relapsed refractory multiple myeloma patients with moderately impaired renal function. Two preclinical data presentations show the future potential of melflufen in treatments of other hematological diseases outside multiple myeloma. In addition, the last preclinical data presentation provides an increased understanding of melflufen 's mode of action. 1. Bridge (Op-107): A Phase 2 Pharmacokinetic Study Of Melflufen Plus Dexamethasone In Patients With Relapsed/Refractory Multiple Myeloma And Impaired Renal Function: The study demonstrates that for patients receiving melflufen in the phase 2 BRIDGE study, the exposure to melphalan increased with reduced eGFR (Estimated Glomerular Filtration Rate), similar to what is observed during treatment with melphalan. The overall toxicity profile was as expected for melflufen and dexamethasone and no new safety signals were observed, supporting the use of melflufen in patients with moderate renal impairment. 2. Melflufen Demonstrates High Efficacy In Cytarabine And Venetoclax Resistant Aml Models: The study shows that multiple aminopeptidases are highly expressed in AML-samples, providing a good rationale for using melflufen therapy. Patients with Acute Myeloid Leukemia, often develop resistance to current treatments, including cytarabine and venetoclax, yet in pre-clinical models of resistance to these agents, melflufen shows high efficacy. 3. Melphalan Flufenamide Is A Highly Potent Anti-Neoplastic Agent In High Risk Dlbcl Models: Several aminopeptidase genes are highly expressed in samples of patients with DLBCL, Diffuse Large B-Cell Lymphoma, and their elevated expression is associated with significantly shorter survival. In preclinical in vitro tests of DLBCL cell lines, melflufen shows superior cytotoxicity compared to Standard of Care drugs doxorubicin and bendamustine. 4. Melflufen Rapidly Accumulates Within Tumor Cells And Distributes An Alkylating Payload To The Nucleus And Mitochondria: The increased lipophilicity of melflufen can affect the redistribution of the alkylating payload within the cell. Data show that melflufen, but not melphalan, localized significantly within lysosomes, endoplasmic reticulum and importantly mitochondria, which may affect the mechanism of cancer cell killing.Reported Earnings • Feb 18First half 2021 earnings released: UK£0.041 loss per share (vs UK£0.083 loss in 1H 2020)The company reported a solid first half result with reduced losses, improved revenues and improved control over expenses. First half 2021 results: Revenue: UK£1.83m (up 493% from 1H 2020). Net loss: UK£2.60m (loss narrowed 51% from 1H 2020). Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings.Is New 90 Day High Low • Feb 13New 90-day high: €2.12The company is up 15% from its price of €1.85 on 13 November 2020. The German market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 12% over the same period.お知らせ • Jan 25Oncimmune Holdings plc to Report First Half, 2021 Results on Feb 15, 2021Oncimmune Holdings plc announced that they will report first half, 2021 results on Feb 15, 2021お知らせ • Jan 22Oncimmune Holdings plc Announces Steps Down of Cheung to as a Non-Executive Director, Effective 19 January 2021Oncimmune Holdings plc announced that Dr Cheung To ("CT") has stepped down as a non-executive Director of the Company, effective from 19 January 2021. Dr To remains a Director of Genostics Company Limited ("Genostics"), part of the Gene Group Holdings Limited ("GGH") group, and stepping down is expected to enable Dr To focus on the continued development of GGH as it prepares for its future corporate and commercial activities. Genostics remains a significant shareholder of Oncimmune and its recent disposal of shares in Oncimmune, bringing its holding to below 10%, was undertaken in line with GGH's preparation for its anticipated corporate activities. Genostics remains Oncimmune's exclusive partner in China and continues to work closely with Oncimmune to gain market entry.Is New 90 Day High Low • Dec 16New 90-day high: €2.04The company is up 32% from its price of €1.55 on 17 September 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.お知らせ • Dec 15Oncimmune Holdings plc Signs Commercial ContractsOncimmune Holdings plc announced that it has signed a commercial contract to supply its EarlyCDT Lung blood test to NHS Norfolk & Waveney Clinical Commissioning Group. Additionally, the Company has also signed a commercial contract to supply EarlyCDT Lung blood test into the NHS Lung Health Check Programmes in Wessex and Yorkshire as part of the iDx-LUNG evaluation programme. Following in-depth due diligence by the NHS, the Company has also been notified that The National Institute for Health and Care Excellence (NICE) has selected the EarlyCDT Lung blood test for Diagnostics Assessment Guidance. This decision follows the publication by NICE in March 2020 of the positive Medtech Innovation Briefing 209 on 'EarlyCDT-Lung for cancer risk classification of indeterminate pulmonary nodules'. The successful completion of this assessment will further support wider market adoption of EarlyCDT Lung in the NHS.Is New 90 Day High Low • Nov 25New 90-day high: €1.99The company is up 32% from its price of €1.51 on 27 August 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.お知らせ • Nov 10Oncimmune Holdings plc, Annual General Meeting, Nov 30, 2020Oncimmune Holdings plc, Annual General Meeting, Nov 30, 2020, at 10:00 Coordinated Universal Time. Location: offices of Zeus Capital, 10 Old Burlington Street London United KingdomReported Earnings • Oct 30Full year earnings released - €0.13 loss per shareOver the last 12 months the company has reported total losses of UK£8.46m, with losses widening by 5.4% from the prior year.Analyst Estimate Surprise Post Earnings • Oct 30Annual earnings released: Revenue misses expectationsAnnual revenue missed analyst estimates by 54% at UK£509.0k. Revenue is forecast to grow 1,072% over the next year, compared to a 273% growth forecast for the Biotechs industry in Germany.お知らせ • Oct 19Oncimmune Holdings plc to Report Fiscal Year 2020 Results on Oct 30, 2020Oncimmune Holdings plc announced that they will report fiscal year 2020 results on Oct 30, 2020お知らせ • Oct 04Oncimmune Holdings plc Initiates U.S. Expanded Access Program with Melflufen in Triple-Class Refractory Multiple MyelomaOncopeptides AB (publ) announced that the open-label Expanded Access Program, sEAPort, for eligible U.S. patients, is formally open. Melflufen (INN melphalan flufenamide), is currently being evaluated in several clinical studies as a treatment for patients with triple-class refractory multiple myeloma. The sEAPort program is available to adults, age 18 and older, who have received at least two prior lines of therapy and whose multiple myeloma is refractory to at least one proteasome inhibitor, one immunomodulatory drug and one anti-CD38 monoclonal antibody, (i.e., triple-class refractory multiple myeloma patients). The Expanded Access Program was initiated following the Company's June 30 submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration, FDA, for accelerated approval of melflufen in combination with dexamethasone for the treatment of adult patients with triple-class refractory multiple myeloma. The NDA and the sEAPort program are primarily supported by data from the pivotal phase 2 HORIZON study, which demonstrates that melflufen in combination with dexamethasone, has a potential to provide a therapeutic option for patients with relapsed refractory multiple myeloma who are hard to treat and have a poor prognosis, including patients with triple-class refractory multiple myeloma and patients with extramedullary disease. EAPs are designed to provide patients living with serious or life-threatening conditions access to investigational medicines when no comparable or satisfactory treatment options are available, alternative therapies have been exhausted or the patient is ineligible for ongoing interventional trials.お知らせ • Sep 26Oncimmune Holdings plc announced that it has received £5.25 million in funding from Balderton Capital (UK) LLP and other investorsOncimmune Holdings plc announced that it has received £5.25 million in funding led by new investor, Balderton Capital (UK) LLP in 2007. As a part of the transaction, Tim Bunting joined the company’s board of directors.お知らせ • Sep 24Oncimmune Holdings plc Signs Collaboration with GenentechOncimmune Holdings plc announced that it has signed a collaboration with Genentech, a member of the Roche Group, to characterise the autoantibody profiles of patients in clinical trials for rheumatological diseases, including Systemic Lupus Erythematosus (SLE). In this new project, Oncimmune will use its proprietary NavigAID panel to characterise autoantibody profiles from trial participants. Following completion of this project, Genentech has the option to expand the contract to profile additional samples. SLE is a chronic, incurable autoimmune disease associated with multiple symptoms that can flare up over time. Diagnosis of SLE can be challenging. An objective of the project includes better characterisation of the disease, where there is a high unmet need for an effective therapy. This project builds upon Oncimmune's broadening commercial footprint to not only deliver diagnostic tests, through EarlyCDT Lung and Liver, but also to partner with large pharmaceutical companies by profiling autoantibodies and developing commercial companion diagnostic tests through Oncimmune's ImmunoINSIGHTS service business.お知らせ • Jun 18An unknown buyer acquired an unknown stake in Oncimmune Holdings plc (AIM:ONC) from University of Nottingham.An unknown buyer acquired an unknown stake in Oncimmune Holdings plc (AIM:ONC) from University of Nottingham on June 15, 2020. The transaction is valued for approximately £1.5 million. An unknown buyer completed the acquisition of an unknown stake in Oncimmune Holdings plc (AIM:ONC) from University of Nottingham on June 15, 2020.株主還元OCYDE BiotechsDE 市場7D0%2.1%1.3%1Y-95.5%5.8%0.9%株主還元を見る業界別リターン: OCY過去 1 年間で5.8 % の収益を上げたGerman Biotechs業界を下回りました。リターン対市場: OCYは、過去 1 年間で0.9 % のリターンを上げたGerman市場を下回りました。価格変動Is OCY's price volatile compared to industry and market?OCY volatilityOCY Average Weekly Movement33.5%Biotechs Industry Average Movement7.0%Market Average Movement5.3%10% most volatile stocks in DE Market12.6%10% least volatile stocks in DE Market2.7%安定した株価: OCYの株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: OCYの 週次ボラティリティ は、過去 1 年間で17%から33%に増加しました。会社概要設立従業員CEO（最高経営責任者ウェブサイト201540Martin Gouldstonewww.oncimmune.comプレシジョン・メディシン企業であるOncimmune Holdings plcは、免疫腫瘍学、自己免疫疾患、感染症における自己抗体バイオマーカー・プロファイリングを欧州および国際的に提供している。同社は、新規バイオマーカーの発見と検証、薬剤の作用機序の検証、治療反応と有害事象（irAE）の予測、患者スクリーニング、診断精度の向上のための知見を提供する自己抗体プロファイリングサービスであるImmunoINSIGHTSプラットフォーム、標的探索やコンパニオン診断のための関連バイオマーカープールを同定するための探索エンジンであるSero Tag、疾患特異的バイオマーカーパネルを作成するためのNavigAID、コンパニオン診断用バイオマーカーであるAutoantibody Biomarkersを提供している。また、事業開発やマーケティングサービスも提供している。Oncimmune Holdings plcは2015年に設立され、英国リーズに本社を置いている。もっと見るOncimmune Holdings plc 基礎のまとめOncimmune Holdings の収益と売上を時価総額と比較するとどうか。OCY 基礎統計学時価総額€1.50m収益（TTM）-€4.11m売上高(TTM)€3.22m0.5xP/Sレシオ-0.4xPER（株価収益率OCY は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計OCY 損益計算書（TTM）収益UK£2.74m売上原価UK£1.51m売上総利益UK£1.23mその他の費用UK£4.73m収益-UK£3.50m直近の収益報告Aug 31, 2024次回決算日該当なし一株当たり利益（EPS）-0.031グロス・マージン44.94%純利益率-127.71%有利子負債／自己資本比率-211.2%OCY の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/04/28 07:59終値2025/03/17 00:00収益2024/08/31年間収益2024/08/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Oncimmune Holdings plc 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Scott BardoBerenbergStuart HarrisCavendishEmma UlkerZeus Capital Limited
New Risk • Feb 13New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €9.29m (US$9.66m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Negative equity (-UK£2.4m). Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Market cap is less than US$10m (€9.29m market cap, or US$9.66m). Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£207k net loss next year). Share price has been volatile over the past 3 months (7.3% average weekly change). Revenue is less than US$5m (UK£2.7m revenue, or US$3.4m).
Reported Earnings • Feb 11Full year 2024 earnings released: UK£0.047 loss per share (vs UK£0.085 loss in FY 2023)Full year 2024 results: UK£0.047 loss per share (improved from UK£0.085 loss in FY 2023). Revenue: UK£2.74m (up 138% from FY 2023). Net loss: UK£3.50m (loss narrowed 43% from FY 2023). Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has fallen by 61% per year, which means it is significantly lagging earnings.
お知らせ • Feb 03Oncimmune Holdings plc, Annual General Meeting, Feb 27, 2025Oncimmune Holdings plc, Annual General Meeting, Feb 27, 2025. Location: 201 temple chambers, 3 7 temple avenue, ec4y 0dt, london United Kingdom
お知らせ • Jan 31Oncimmune Holdings plc Provides Revenue Guidance for the First Half and for the Fiscal Year 2025Oncimmune Holdings plc provided revenue guidance for the first half of fiscal year 2025. For the period, the company's revenue is likely to be approximately £1.4 million, an increase of circa 20% on the prior year (£1.19 million) and the Company continues to add to its broad pipeline of potential contracts. For the year 2025, the company expects revenue to be in the region of £4 million, which would be an uplift of 33% vs FY2024 and growth of around 250% vs FY2023. The company expects to have much greater visibility on its revenue in the second half of the financial year.
New Risk • Dec 08New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended February 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Negative equity (-UK£1.3m). Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported February 2024 fiscal period end). Currently unprofitable and not forecast to become profitable next year (UK£1.4m net loss next year). Share price has been volatile over the past 3 months (11% average weekly change). Revenue is less than US$5m (UK£1.2m revenue, or US$1.5m). Market cap is less than US$100m (€20.9m market cap, or US$22.1m).
New Risk • Nov 14New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 51% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Negative equity (-UK£1.3m). Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£1.4m net loss next year). Revenue is less than US$5m (UK£1.2m revenue, or US$1.5m). Market cap is less than US$100m (€20.8m market cap, or US$21.9m).
New Risk • Feb 13New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €9.29m (US$9.66m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Negative equity (-UK£2.4m). Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Market cap is less than US$10m (€9.29m market cap, or US$9.66m). Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£207k net loss next year). Share price has been volatile over the past 3 months (7.3% average weekly change). Revenue is less than US$5m (UK£2.7m revenue, or US$3.4m).
Reported Earnings • Feb 11Full year 2024 earnings released: UK£0.047 loss per share (vs UK£0.085 loss in FY 2023)Full year 2024 results: UK£0.047 loss per share (improved from UK£0.085 loss in FY 2023). Revenue: UK£2.74m (up 138% from FY 2023). Net loss: UK£3.50m (loss narrowed 43% from FY 2023). Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has fallen by 61% per year, which means it is significantly lagging earnings.
お知らせ • Feb 03Oncimmune Holdings plc, Annual General Meeting, Feb 27, 2025Oncimmune Holdings plc, Annual General Meeting, Feb 27, 2025. Location: 201 temple chambers, 3 7 temple avenue, ec4y 0dt, london United Kingdom
お知らせ • Jan 31Oncimmune Holdings plc Provides Revenue Guidance for the First Half and for the Fiscal Year 2025Oncimmune Holdings plc provided revenue guidance for the first half of fiscal year 2025. For the period, the company's revenue is likely to be approximately £1.4 million, an increase of circa 20% on the prior year (£1.19 million) and the Company continues to add to its broad pipeline of potential contracts. For the year 2025, the company expects revenue to be in the region of £4 million, which would be an uplift of 33% vs FY2024 and growth of around 250% vs FY2023. The company expects to have much greater visibility on its revenue in the second half of the financial year.
New Risk • Dec 08New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended February 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Negative equity (-UK£1.3m). Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported February 2024 fiscal period end). Currently unprofitable and not forecast to become profitable next year (UK£1.4m net loss next year). Share price has been volatile over the past 3 months (11% average weekly change). Revenue is less than US$5m (UK£1.2m revenue, or US$1.5m). Market cap is less than US$100m (€20.9m market cap, or US$22.1m).
New Risk • Nov 14New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 51% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Negative equity (-UK£1.3m). Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£1.4m net loss next year). Revenue is less than US$5m (UK£1.2m revenue, or US$1.5m). Market cap is less than US$100m (€20.8m market cap, or US$21.9m).
Breakeven Date Change • Oct 24No longer forecast to breakevenThe analyst covering Oncimmune Holdings no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of UK£552.0k in 2025. New forecast suggests the company will make a loss of UK£207.0k in 2025.
New Risk • Sep 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (15% average weekly change). Minor Risk Market cap is less than US$100m (€17.0m market cap, or US$18.9m).
お知らせ • Aug 10Oncimmune Holdings plc Reaffirms Revenue Guidance for the Fiscal Year 2024 and Provides Earnings Guidance for the Fiscal Year 2025Oncimmune Holdings plc reaffirmed revenue guidance for the fiscal year 2024 and provided earnings guidance for the fiscal year 2025. The continued commercial traction, and expected acceleration due to the new commercial team fully bedding in, give Oncimmune's Board confidence in its revenue guidance for fiscal year 2024 of approximately £3 million (2023: £1.15 million from continuing operations). On the back of continued revenue growth, the Board expects the Company to achieve profitability in fiscal year 2025.
New Risk • Jun 10New major risk - Negative shareholders equityThe company has negative equity. Total equity: -UK£1.3m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£6.1m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Negative equity (-UK£1.3m). Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£1.1m net loss next year). Revenue is less than US$5m (UK£1.2m revenue, or US$1.5m). Market cap is less than US$100m (€14.0m market cap, or US$15.1m).
お知らせ • May 19Oncimmune Holdings plc to Report First Half, 2024 Results on May 21, 2024Oncimmune Holdings plc announced that they will report first half, 2024 results on May 21, 2024
Board Change • May 16Less than half of directors are independentThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 3 new directors. 4 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). Member of Scientific Board Ola Winqvist is the most experienced director on the board, commencing their role in 2018. Independent Non-Executive Director John Goold was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.
Reported Earnings • Mar 01Full year 2023 earnings released: UK£0.085 loss per share (vs UK£0.13 loss in FY 2022)Full year 2023 results: UK£0.085 loss per share (improved from UK£0.13 loss in FY 2022). Revenue: UK£1.15m (down 62% from FY 2022). Net loss: UK£6.15m (loss narrowed 33% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 53% per year, which means it is performing significantly worse than earnings.
お知らせ • Mar 01Oncimmune Holdings plc Provides Earnings Guidance for the Year 2024Oncimmune Holdings plc provided earnings guidance for the year 2024. For the period, the company expects revenue to be approximately £3 million, compared with Fiscal Year 2023 revenue from continuing operations of £1.2 million, a growth rate of 150%. Coming up to the end of H1 Fiscal Year 2024, work to achieve approximately 75% of the forecast Fiscal Year 2024 revenue has been secured, with the majority of samples received or expected imminently allowing lab work to begin and revenue to be recognised in due course.
お知らせ • Feb 02Oncimmune Holdings plc, Annual General Meeting, Feb 26, 2024Oncimmune Holdings plc, Annual General Meeting, Feb 26, 2024, at 10:00 Coordinated Universal Time. Location: At the offices of Singer Capital Markets, 1 Bartholomew Lane London United Kingdom
New Risk • Jan 30New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended August 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Negative equity (-UK£4.2m). Revenue has declined by 14% over the past year. Minor Risks Latest financial reports are more than 6 months old (reported August 2022 fiscal period end). Share price has been volatile over the past 3 months (9.6% average weekly change). Revenue is less than US$5m (UK£3.0m revenue, or US$3.8m). Market cap is less than US$100m (€21.5m market cap, or US$23.3m).
お知らせ • Nov 30Oncimmune Holdings plc Announces Board ChangesOncimmune Holdings plc announced on 12 October 2023, Dr. Annalisa Jenkins has decided to step down from the Board and a new Senior Independent Non-Executive Director, Sally Waterman, has been appointed. The transition of Annalisa's responsibilities has now been completed and she has therefore ceased to be a director with immediate effect.
Board Change • Nov 02Less than half of directors are independentThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 4 new directors. 5 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Non-Executive Director Annalisa Jenkins is the most experienced director on the board, commencing their role in 2018. Senior Independent Non-Executive Director Sally Waterman was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.
お知らせ • Oct 12Oncimmune Holdings plc Announces Changes to the BoardOncimmune's new focus on its ImmunoINSIGHTS business, having disposed of its early cancer diagnostic business in May 2023, the composition of Oncimmune's board of directors (the "Board") is undergoing further change. Tim Bunting, who has been a director of Oncimmune since 2016, has stepped down from the Board with immediate effect. Tim was one of Oncimmune's earliest investors and continued to support it for over 15 years, many of them as a non-executive director. Tim remains a major shareholder of Oncimmune, having supported its latest fundraise in December 2022, and has given his full backing to the Company's new management team. Dr Annalisa Jenkins has also decided to step down from the Board by the end of 2023. Annalisa has been a director of Oncimmune since January 2018 and has served as the Company's Senior Independent Director and Chair of its Remuneration Committee. To replace Dr Annalisa Jenkins, Oncimmune announced the appointment of Sally Waterman. Sally has over 30 years of strategic and operational experience in the life science industry, including leading R&D and extensive involvement in M&A, and has worked for large pharma, small biotech/biopharma and contract service companies. Once all of the changes set out above are completed, and following the departure of Andrew Unitt as previously announced on 12 July 2023, the Board will consist of Alistair Macdonald (Non-executive Chair), Dr Sally Waterman (Senior Independent Non-executive Director and Chair of the Remuneration Committee), John Goold (Independent Non-executive Director and Chair of the Audit Committee) and Martin Gouldstone (Chief Executive Officer).
お知らせ • Aug 02+ 1 more updateOncimmune Holdings plc Announces Executive ChangesOncimmune Holdings plc announced that Martin Gouldstone has started as the Company's new Chief Executive Officer and joined the Board of Directors. With Martin as Chief Executive Officer, Ron Kirschner, who was appointed as acting Chief Executive Officer in June, will be taking up the role of Chief Operating Officer and has stepped down from the Board. Ron remains Oncimmune's Company Secretary.
お知らせ • May 23Freenome Holdings, Inc. acquired Oncimmune Limited and Oncimmune Europe GmbH from Oncimmune Holdings plc (AIM:ONC) for £13 million.Freenome Holdings, Inc. acquired Oncimmune Limited and Oncimmune Europe GmbH from Oncimmune Holdings plc (AIM:ONC) for £13 million on May 22, 2023. The consideration of £13 million is in cash, structured as consideration for equity and debt repayment, of which £1.3 million in cash is being held in escrow for 12 months in the event of any claim by Freenome against the customary warranties and indemnity given to Freenome in the sale and purchase agreement. Separately, Oncimmune Germany GmbH, Oncimmune Holdings' wholly-owned pharma services business trading as ImmunoINSIGHTS, and Freenome have also signed a long-term Master Services Agreement. Oncimmune Holdings has an existing debt facility with IPF Management SA with an outstanding principal balance of €11.6 million prior to this transaction. In connection with the transaction, Oncimmune has agreed to repay €7.2 million (being €5.6 million of principal and €1.6 million of interest) of the outstanding IPF Facility. The Board of Oncimmune Holdings considers that the repayment of debt under the IPF Facility, the repayment profile of the new IPF Facility, together with the net proceeds from the transaction, removes any material uncertainty as regards going concern. Phil Davies, Harry Gooden, George Tzimas and James Fischer of Nplus1 Singer Advisory LLP acted as the financial advisor to Oncimmune Holdings plc (AIM:ONC).Freenome Holdings, Inc. completed the acquisition of Oncimmune Limited and Oncimmune Europe GmbH from Oncimmune Holdings plc (AIM:ONC) for £13 million on May 22, 2023.
お知らせ • Feb 04Oncimmune Holdings plc, Annual General Meeting, Feb 27, 2023Oncimmune Holdings plc, Annual General Meeting, Feb 27, 2023, at 10:00 Coordinated Universal Time. Location: offices of Pinsent,Masons LLP, 30 Crown Place, Earl Street, London, EC2A 4ES London United Kingdom
お知らせ • Jan 13Oncimmune Holdings plc Announces Appointment of John Goold as Non-Executive DirectorOncimmune Holdings plc announced that further to the announcement made on 7 December 2022, John Goold has been appointed to the Board of the Company as Non-Executive Director with immediate effect, following the successful completion of customary due diligence checks by the Company's Nominated Adviser. Additional Information in respect of the AIM Rules: The following information regarding the appointment of John Howard Goold, aged 51, is disclosed under Schedule 2(g) of the AIM Rules for Companies.
お知らせ • Dec 15Oncimmune Holdings plc has completed a Follow-on Equity Offering in the amount of £2.1 million.Oncimmune Holdings plc has completed a Follow-on Equity Offering in the amount of £2.1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 2,622,221 Price\Range: £0.45 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 2,044,446 Price\Range: £0.45
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Senior Independent Non-Executive Director Annalisa Jenkins was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Sep 22Full year 2022 earnings released: UK£0.14 loss per share (vs UK£0.072 loss in FY 2021)Full year 2022 results: UK£0.14 loss per share (further deteriorated from UK£0.072 loss in FY 2021). Revenue: UK£3.86m (up 3.7% from FY 2021). Net loss: UK£9.51m (loss widened 106% from FY 2021). Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
Buying Opportunity • Aug 01Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 29%. The fair value is estimated to be €1.19, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 92% over the last 3 years. Earnings per share has grown by 17%.
お知らせ • Jul 08Oncimmune Holdings plc Announces Board ChangesOncimmune Holdings plc announced the appointment of Alistair Macdonald as Non-executive Chair, effective immediately. Alistair succeeds Meinhard Schmidt as Chair of the Board, who has retired from the Board. Alistair brings a wealth of knowledge in the pharma services sector, developed through his 25-year career in life sciences, culminating in his role as CEO of leading, integrated CRO Syneos Health Inc. (Nasdaq: SYNH; market cap c.$6.6 billion) ("Syneos"), which he held for 6 years, before which he was CEO of INC Research which merged with inVentiv Health to become Syneos in 2017. During his time with INC and then Syneos, revenue grew from $20m to over $5.0 billion. Prior to becoming a CEO, Alistairled multiple functions including Global Business Development and Marketing, Alliances Development and Delivery, Global Oncology, and Clinical Development Services. Over the last 25 years, he has held management positions in the pharmaceutical industry across manufacturing, consultancy, business and corporate development, data management and clinical operations. Alistair retired as CEO of Syneos Health in April 2022, a company that he led post-merger through further substantial organic as well as inorganic growth. Alistair led the merger that formed Syneos, which brought together approximately 24,000 employees serving customers in 110 countries with innovative, end-to-end solutions to accelerate their clinical development and commercialisation timelines. Until recently, Alistair has also served as Chair of ACRO, the Association of Clinical Research Organisations, having been on its board for approximately seven years.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 1 highly experienced director. 2 independent directors (3 non-independent directors). Senior Independent Non-Executive Director Annalisa Jenkins was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Mar 02First half 2022 earnings: EPS in line with expectations, revenues disappointFirst half 2022 results: UK£0.07 loss per share (down from UK£0.041 loss in 1H 2021). Revenue: UK£1.43m (down 22% from 1H 2021). Net loss: UK£4.86m (loss widened 87% from 1H 2021). Revenue missed analyst estimates by 34%. Over the next year, revenue is forecast to grow 316%, compared to a 64% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth.
お知らせ • Feb 25+ 1 more updateOncimmune Holdings Ordinary Shares to Be Deleted from Other OTCOncimmune Holdings plc's Ordinary Shares will be deleted from other OTC effective from February 24, 2022 due to Inactive Security.
お知らせ • Feb 18Oncimmune Holdings plc Announces EarlyCDT Lung Test Approved by Ministry of Health for Aragon, SpainOncimmune Holdings plc announced that the Regional Ministry of Health for Aragon, Spain has announced that the Company's Early CDT Lung blood test is to be adopted by the Thoracic Surgery Unit of the University Hospital Miguel Servet, Zaragoza, for use on solitary pulmonary nodules. This approval follows the issuing of a favourable assessment and report by the Evaluation Committee of the Aragonese Health System having met the necessary criteria with regards to efficacy and safety. The issuing of this positive assessment by the Aragon Public Health Service and the subsequent approval is considered an important development by Oncimmune and its Spanish distributor, Sabartech, towards the adoption of the blood test by other regional public health systems in Spain. This latest approval in Spain follows an earlier announcement on 2 November 2021 that EarlyCDT Lung had been authorised for use within the Spanish Public Health Service by the Galician Health Service (SERGAS), the first public health service in Spain to use the EarlyCDT Lung test.
Reported Earnings • Nov 04Full year 2021 earnings released: UK£0.072 loss per share (vs UK£0.13 loss in FY 2020)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: UK£3.72m (up UK£3.21m from FY 2020). Net loss: UK£4.63m (loss narrowed 45% from FY 2020). Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has increased by 22% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Jul 24Oncimmune Holdings plc Announces the Pre-Publication of the First Results from Its Collaboration with Cedars-Sinai Medical Center in Los AngelesOncimmune Holdings plc announced the pre-publication of the first results from its collaboration with Cedars-Sinai Medical Center in Los Angeles, entitled: "Paradoxical Sex-Specific Patterns of Autoantibodies Response to SARS-CoV-2 Infection"1. The paper focuses on the characterisation of sex-specific prevalence and selectivity of autoantibody responses to the SARS-CoV-2 virus. Since the beginning of the COVID-19 pandemic, there has been an unprecedented number of initiatives from the life sciences industry and research institutions to understand and respond to the effects of COVID-19, but despite first generation vaccines now being deployed to fight the disease, the need to expand understanding of the immune response to SARS-CoV-2 still exists. The results of this study demonstrate the potential of the SeroTagTM Infectious Diseases discovery array to enable a better understanding of how SARS-CoV-2 stimulates the immune reaction and predicts responses to vaccines and therapeutics against the virus. The aim of this initial research project was to use the SeroTag Infectious Diseases discovery array to detect autoantibodies to over 90 antigens previously linked to a range of classic autoimmune diseases. The researchers sought to comprehensively examine the diversity of autoantibody responses in male and female health care workers who were exposed to SARS-CoV-2 and were asymptomatic, or experienced minor symptoms.
お知らせ • May 21Oncimmune Holdings plc Presents Clinical Abstracts on Melflufen At the 2021 American Society of Clinical OncologyOncopeptides AB (publ) announces that three abstracts with data on melflufen (INN melphalan flufenamide) in relapsed refractory multiple myeloma, RRMM, have been accepted by the 2021 American Society of Clinical Oncology, ASCO, and have now been published online. The clinical data presentations include updates on Oncopeptides' ANCHOR and LIGHTHOUSE studies as well as a pooled analysis of the O-12-M1 and HORIZON studies in patients who have been exposed to or become refractory to prior alkylators. Below is a brief description of the abstracts that have been accepted by the ASCO. They will be available online at https://www.asco.org, on May 19th at 23:00 (CET). 1. ANCHOR (OP-104): MELFLUFEN PLUS DEXAMETHASONE AND BORTEZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS The ANCHOR study determined that the optimal dose of melflufen is 30 mg plus dexamethasone and bortezomib and the results showed clinical activity in heavily pretreated RRMM patients. Recruitment for this study is ongoing and updated data including efficacy and safety will be presented at ASCO. 2. LIGHTHOUSE (OP-108): A PHASE 3 STUDY OF MELFLUFEN IN COMBINATION WITH DEXAMETHASONE AND DARATUMUMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS The phase 3 LIGHTHOUSE study is a randomized, controlled, open-label study of melflufen plus dexamethasone in combination with daratumumab vs daratumumab alone in patients with RRMM previously treated with an immunomodulatory agent and a proteasome inhibitor, similar to the indication for daratumumab monotherapy. The primary objective is superiority of PFS. Key secondary endpoints include ORR (= PR), DOR, and safety. Patient recruitment is ongoing with a planned enrolment of 240 patients. 3. A POOLED ANALYSIS OF THE O-12-M1 AND HORIZON STUDIES: MELFLUFEN PLUS DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS (RRMM) WHO ARE EXPOSED OR REFRACTORY TO PRIOR ALKYLATORS This pooled analysis of the O-12-M1 and HORIZON studies showed that melflufen in combination with dexamethasone showed meaningful efficacy and demonstrated a clinically manageable safety profile in patients with RRMM who had been exposed or become refractory to prior alkylators. PEPAXTO® (melphalan flufenamide, also known as melflufen), in combination with dexamethasone, was granted accelerated approval by the FDA on February 26, 2021, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD38-directed monoclonal antibody.
お知らせ • May 13Oncopeptides AB (publ) Presents New Clinical and Preclinical Melflufen Data At the Upcoming European Hematology Association MeetingOncopeptides AB (publ) announces that new clinical and preclinical data have been accepted by the European Hematology Association, EHA, and been published online. The clinical data presentation contains interim results from the phase 2 BRIDGE study supporting the use of melflufen in relapsed refractory multiple myeloma patients with moderately impaired renal function. Two preclinical data presentations show the future potential of melflufen in treatments of other hematological diseases outside multiple myeloma. In addition, the last preclinical data presentation provides an increased understanding of melflufen 's mode of action. 1. Bridge (Op-107): A Phase 2 Pharmacokinetic Study Of Melflufen Plus Dexamethasone In Patients With Relapsed/Refractory Multiple Myeloma And Impaired Renal Function: The study demonstrates that for patients receiving melflufen in the phase 2 BRIDGE study, the exposure to melphalan increased with reduced eGFR (Estimated Glomerular Filtration Rate), similar to what is observed during treatment with melphalan. The overall toxicity profile was as expected for melflufen and dexamethasone and no new safety signals were observed, supporting the use of melflufen in patients with moderate renal impairment. 2. Melflufen Demonstrates High Efficacy In Cytarabine And Venetoclax Resistant Aml Models: The study shows that multiple aminopeptidases are highly expressed in AML-samples, providing a good rationale for using melflufen therapy. Patients with Acute Myeloid Leukemia, often develop resistance to current treatments, including cytarabine and venetoclax, yet in pre-clinical models of resistance to these agents, melflufen shows high efficacy. 3. Melphalan Flufenamide Is A Highly Potent Anti-Neoplastic Agent In High Risk Dlbcl Models: Several aminopeptidase genes are highly expressed in samples of patients with DLBCL, Diffuse Large B-Cell Lymphoma, and their elevated expression is associated with significantly shorter survival. In preclinical in vitro tests of DLBCL cell lines, melflufen shows superior cytotoxicity compared to Standard of Care drugs doxorubicin and bendamustine. 4. Melflufen Rapidly Accumulates Within Tumor Cells And Distributes An Alkylating Payload To The Nucleus And Mitochondria: The increased lipophilicity of melflufen can affect the redistribution of the alkylating payload within the cell. Data show that melflufen, but not melphalan, localized significantly within lysosomes, endoplasmic reticulum and importantly mitochondria, which may affect the mechanism of cancer cell killing.
Reported Earnings • Feb 18First half 2021 earnings released: UK£0.041 loss per share (vs UK£0.083 loss in 1H 2020)The company reported a solid first half result with reduced losses, improved revenues and improved control over expenses. First half 2021 results: Revenue: UK£1.83m (up 493% from 1H 2020). Net loss: UK£2.60m (loss narrowed 51% from 1H 2020). Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings.
Is New 90 Day High Low • Feb 13New 90-day high: €2.12The company is up 15% from its price of €1.85 on 13 November 2020. The German market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 12% over the same period.
お知らせ • Jan 25Oncimmune Holdings plc to Report First Half, 2021 Results on Feb 15, 2021Oncimmune Holdings plc announced that they will report first half, 2021 results on Feb 15, 2021
お知らせ • Jan 22Oncimmune Holdings plc Announces Steps Down of Cheung to as a Non-Executive Director, Effective 19 January 2021Oncimmune Holdings plc announced that Dr Cheung To ("CT") has stepped down as a non-executive Director of the Company, effective from 19 January 2021. Dr To remains a Director of Genostics Company Limited ("Genostics"), part of the Gene Group Holdings Limited ("GGH") group, and stepping down is expected to enable Dr To focus on the continued development of GGH as it prepares for its future corporate and commercial activities. Genostics remains a significant shareholder of Oncimmune and its recent disposal of shares in Oncimmune, bringing its holding to below 10%, was undertaken in line with GGH's preparation for its anticipated corporate activities. Genostics remains Oncimmune's exclusive partner in China and continues to work closely with Oncimmune to gain market entry.
Is New 90 Day High Low • Dec 16New 90-day high: €2.04The company is up 32% from its price of €1.55 on 17 September 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
お知らせ • Dec 15Oncimmune Holdings plc Signs Commercial ContractsOncimmune Holdings plc announced that it has signed a commercial contract to supply its EarlyCDT Lung blood test to NHS Norfolk & Waveney Clinical Commissioning Group. Additionally, the Company has also signed a commercial contract to supply EarlyCDT Lung blood test into the NHS Lung Health Check Programmes in Wessex and Yorkshire as part of the iDx-LUNG evaluation programme. Following in-depth due diligence by the NHS, the Company has also been notified that The National Institute for Health and Care Excellence (NICE) has selected the EarlyCDT Lung blood test for Diagnostics Assessment Guidance. This decision follows the publication by NICE in March 2020 of the positive Medtech Innovation Briefing 209 on 'EarlyCDT-Lung for cancer risk classification of indeterminate pulmonary nodules'. The successful completion of this assessment will further support wider market adoption of EarlyCDT Lung in the NHS.
Is New 90 Day High Low • Nov 25New 90-day high: €1.99The company is up 32% from its price of €1.51 on 27 August 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
お知らせ • Nov 10Oncimmune Holdings plc, Annual General Meeting, Nov 30, 2020Oncimmune Holdings plc, Annual General Meeting, Nov 30, 2020, at 10:00 Coordinated Universal Time. Location: offices of Zeus Capital, 10 Old Burlington Street London United Kingdom
Reported Earnings • Oct 30Full year earnings released - €0.13 loss per shareOver the last 12 months the company has reported total losses of UK£8.46m, with losses widening by 5.4% from the prior year.
Analyst Estimate Surprise Post Earnings • Oct 30Annual earnings released: Revenue misses expectationsAnnual revenue missed analyst estimates by 54% at UK£509.0k. Revenue is forecast to grow 1,072% over the next year, compared to a 273% growth forecast for the Biotechs industry in Germany.
お知らせ • Oct 19Oncimmune Holdings plc to Report Fiscal Year 2020 Results on Oct 30, 2020Oncimmune Holdings plc announced that they will report fiscal year 2020 results on Oct 30, 2020
お知らせ • Oct 04Oncimmune Holdings plc Initiates U.S. Expanded Access Program with Melflufen in Triple-Class Refractory Multiple MyelomaOncopeptides AB (publ) announced that the open-label Expanded Access Program, sEAPort, for eligible U.S. patients, is formally open. Melflufen (INN melphalan flufenamide), is currently being evaluated in several clinical studies as a treatment for patients with triple-class refractory multiple myeloma. The sEAPort program is available to adults, age 18 and older, who have received at least two prior lines of therapy and whose multiple myeloma is refractory to at least one proteasome inhibitor, one immunomodulatory drug and one anti-CD38 monoclonal antibody, (i.e., triple-class refractory multiple myeloma patients). The Expanded Access Program was initiated following the Company's June 30 submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration, FDA, for accelerated approval of melflufen in combination with dexamethasone for the treatment of adult patients with triple-class refractory multiple myeloma. The NDA and the sEAPort program are primarily supported by data from the pivotal phase 2 HORIZON study, which demonstrates that melflufen in combination with dexamethasone, has a potential to provide a therapeutic option for patients with relapsed refractory multiple myeloma who are hard to treat and have a poor prognosis, including patients with triple-class refractory multiple myeloma and patients with extramedullary disease. EAPs are designed to provide patients living with serious or life-threatening conditions access to investigational medicines when no comparable or satisfactory treatment options are available, alternative therapies have been exhausted or the patient is ineligible for ongoing interventional trials.
お知らせ • Sep 26Oncimmune Holdings plc announced that it has received £5.25 million in funding from Balderton Capital (UK) LLP and other investorsOncimmune Holdings plc announced that it has received £5.25 million in funding led by new investor, Balderton Capital (UK) LLP in 2007. As a part of the transaction, Tim Bunting joined the company’s board of directors.
お知らせ • Sep 24Oncimmune Holdings plc Signs Collaboration with GenentechOncimmune Holdings plc announced that it has signed a collaboration with Genentech, a member of the Roche Group, to characterise the autoantibody profiles of patients in clinical trials for rheumatological diseases, including Systemic Lupus Erythematosus (SLE). In this new project, Oncimmune will use its proprietary NavigAID panel to characterise autoantibody profiles from trial participants. Following completion of this project, Genentech has the option to expand the contract to profile additional samples. SLE is a chronic, incurable autoimmune disease associated with multiple symptoms that can flare up over time. Diagnosis of SLE can be challenging. An objective of the project includes better characterisation of the disease, where there is a high unmet need for an effective therapy. This project builds upon Oncimmune's broadening commercial footprint to not only deliver diagnostic tests, through EarlyCDT Lung and Liver, but also to partner with large pharmaceutical companies by profiling autoantibodies and developing commercial companion diagnostic tests through Oncimmune's ImmunoINSIGHTS service business.
お知らせ • Jun 18An unknown buyer acquired an unknown stake in Oncimmune Holdings plc (AIM:ONC) from University of Nottingham.An unknown buyer acquired an unknown stake in Oncimmune Holdings plc (AIM:ONC) from University of Nottingham on June 15, 2020. The transaction is valued for approximately £1.5 million. An unknown buyer completed the acquisition of an unknown stake in Oncimmune Holdings plc (AIM:ONC) from University of Nottingham on June 15, 2020.
